Background: The World Health Organization (WHO) classification of hematologic malignancies, published in 2000, was designed to improve diagnostic accuracy by incorporating the latest in scientific understanding. The impact of the WHO classification on the frequency of diagnostic discrepancy in lymphoma is unknown.
introduction
The appropriate management of patients with lymphoma depends on an accurate and precise pathologic diagnosis as natural history and optimal treatment vary widely among the different subtypes of lymphoma. However, diagnosis is made challenging by the clinical rarity of individual subtypes of lymphoma in most pathologists' practices, small diagnostic specimens, and morphologic overlap across subtypes. Furthermore, laboratory advances in molecular and genetic studies have led to a greater breadth of available ancillary tests, but limitations in sensitivity and specificity of these studies demand sophistication from the interpreting pathologist.
Previously, multiple competing classification systems resulted in confusion and debate [1] [2] [3] [4] . Consequently, the need for more uniform, reliable and reproducible diagnosis of the lymphomas was a driving force behind the development and adoption of new classification schemata. In 2000, the World Health Organization (WHO) presented a new diagnostic classification built upon the older Revised European-American Classification of Lymphoid Neoplasms (REAL), reinforcing the importance of morphologic, immunophenotypic, molecular, and genetic features in defining disease entities and establishing a single unified classification system [5, 6] . The WHO classification schema has recently been updated, further emphasizing the fundamental importance of these four elements in the diagnosis of lymphoma [7] .
Before the adoption of the original WHO classification, documented rates of discordance on expert review were as high as 43% [8] [9] [10] [11] [12] [13] . Investigations into the pathology review since 2000 have either focused on translating diagnoses from older schemata into WHO terminology or were largely based upon pre-2000 diagnoses. Aside from data presented in abstract form [14] , only one study has investigated pathology discrepancy rates between referral institutions and National Cancer Institute-designated Comprehensive Cancer Centers (NCICCCs) after the WHO classification system had been published [15] . Few data exist addressing possible demographic, pathologic, or clinical features associated with clinically significant diagnostic revisions. In order to test the hypothesis that increased familiarity with the WHO schema is associated with a change in the frequency of major diagnostic revision at 
methods
This retrospective data analysis was approved by the institutional review board and determined to be exempt research. Patient consent was not required.
All outside pathology is routinely reviewed at Memorial Sloan-Kettering Cancer Center (MSKCC) before a clinical opinion is finalized. Institutional standard is to solicit either 2 hematoxylin-and-eosin-stained slides and immunohistochemistry (IHC) or at least 10 unstained slides or the relevant tissue block(s) from previous biopsies. All patients receiving secondopinion pathology review from the MSKCC Department of Pathology from 1 January 2001 to 30 June 2001 and from 1 January 2006 to 30 June 2006 were deemed eligible if records of the original biopsy results were available in the electronic record or obtained after contacting the referring center; no exclusion criteria were applied. All pathologic specimens were reviewed in real time by one of the three pathologists with expertise in hematopathology (JTF, DAF, OL), with cases reviewed at weekly consensus conference. Skin biopsies were separately reviewed by a board-certified dermatopathologist (KJB). Additional evaluation, including immunohistochemical studies, was carried out on select cases as deemed necessary by the interpreting hematopathologist. Original and review pathology reports were evaluated retrospectively, with all original and review diagnoses classified according to the original WHO classification system. Criteria for classifying reports as nondiagnostic or ambiguous were defined a priori; reports were considered nondiagnostic if, after completion of all ancillary testing ordered, a final diagnosis was unable to be rendered and considered ambiguous if the final diagnosis failed to achieve the degree of specificity that would be required to generate a treatment recommendation based upon National Comprehensive Cancer Network (NCCN) guidelines. Thus, while 'T-cell lymphoma' is clinically ambiguous, as NCCN guidelines did not differentiate among subtypes of T-cell lymphoma, and thus was not defined as ambiguous for this study, whereas 'B-cell lymphoma of follicular center cell origin' could represent diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL), disease with different management per NCCN guidelines, and thus would be considered an ambiguous diagnosis in this analysis.
Agreement between the submitted and review diagnosis was analyzed. For patients who had previously received second-opinion pathology consultation, the most recent diagnosis was considered the submitted diagnosis. Diagnostic discrepancies were scored according to an a priori grading schema as agreement, minor discrepancy, or major discrepancy ( Figure 1 ). Major discrepancies were those that would alter management according to guidelines published by the NCCN, and minor discrepancies Figure 1 . Classification of diagnostic revisions. All possible diagnostic revisions were classified a priori based upon clinical relevance as defined by NCCN published guidelines on the diagnosis and management of Hodgkin and non-Hodgkin's lymphoma. Major revisions (changes between fields in zone 1) are those associated with definite changes in management according to NCCN guidelines; minor revisions (changes between fields in zone 2) those with possible changes in management in select cases; and insignificant revisions (changes between fields in zone 3) those that would not be associated with changes in management. NCCN, National Comprehensive Cancer Network.
were those that, while rendering a different diagnosis, would not fundamentally alter management according to NCCN recommendations [16, 17] . Potential factors associated with rate of major diagnostic revision were assessed, including available patient demographic data (age, gender, race, and ethnicity) and clinical features (original diagnosis, type of biopsy, site of biopsy, IHC reviewed at MSKCC, IHC carried out at MSKCC, additional biopsy, and type of referring pathology laboratory). In determining clinical and demographic factors associated with diagnostic revision, statistical analysis was carried out using chi-square or Fisher's exact test for univariate analysis and logistic regression for multivariate analysis. All variables whose univariate tests resulted in a P value £0.10 and variable time period (2006 versus 2001) were considered in the multivariate mode. In addition, for individuals who had previously received a second-opinion pathology review at another NCI-CCC before review at our institution, we evaluated the pattern of revisions comparing the original diagnostic biopsy, the second opinion, and the final MSKCC diagnosis. Table 1 . Predominance of white non-Hispanics and a younger median age than that reported in the general Surveillance Epidemiology and End Results population reflects referral patterns to MSKCC [18] . Hodgkin lymphoma (HL) was overrepresented in comparison with population-based statistics, and the contribution of T-cell lymphomas increased from 2001 to 2006, temporally associated with a development of a focused T-cell lymphoma program in the intervening years. This led to an imbalance between the two time periods in the distribution of referring diagnoses (P = 0.007). None the less, the distribution of lymphoma subtypes from both time periods was otherwise consistent with previous reports of relative frequencies of lymphoma subtypes [12, 16] .
Rates of diagnostic revision at second-opinion pathology review are detailed in Table 2 Among cases reviewed with prior biopsies submitted as nondiagnostic specimens, a diagnosis of lymphoma was rendered based upon available tissue in six cases in 2001 and in eight cases in 2006; an additional seven cases in 2001 were nondiagnostic before review at an NCI-CCC before assessment at MSKCC. Of these 21 cases, 2 were reclassified as HL, 2 as DLBCL, 7 as T-cell lymphomas, 9 as indolent B-cell lymphomas, and 1 as ungraded FL.
In an attempt to characterize what aspects of the secondopinion pathology review contributed to diagnostic revision, we sought to correlate diagnostic revision with patient demographic features, clinical variables, and components of the pathologic evaluation (Tables 4 and 5) . A standard element in the routine pathology review is the review of previously carried out IHC stains and/or repeat or additional IHC carried out on unstained slides. Univariate analyses based on combined 2001 and 2006 data showed IHC carried out at MSKCC, subtype of referral diagnosis, and site of biopsy were significantly associated with major diagnostic revision (Table 4 ; P = 0.03, P < 0.001, and P = 0.02, respectively). Age, gender, race and ethnicity were not associated with a statistically significant difference in odds of receiving a revised diagnosis. Type of biopsy specimen [fine needle aspiration, core biopsy, or incisional biopsy], IHC reviewed at MSKCC, and additional biopsy were also not associated with odds of diagnostic revision. Lastly, no significant association between nature of referring pathology laboratory and odds of diagnostic revision was noted. Discrepancies in cases reviewed previously at another NCCN center existed; in 2001, six such cases occurred: four involved a change in degree of certainty regarding the Relative to B-cell neoplasms, HL was significantly less likely to undergo major diagnostic revision (OR = 0.37, 95% CI 0.17-0.78, P = 0.009), while collectively, diagnoses that were individually uncommon in the referral population-those representing <5% of all referrals-as well as nondiagnostic were more likely to receive revised diagnoses (OR = 3.52, 95% CI 1.37-9.09, P = 0.009; OR = 2.24 95% CI 1.11-4.55, P = 0.03).
discussion
In this article, we report the experience at an NCI-CCC with second-opinion pathology review for patients seen in clinical consultation. Six-month periods in 2001, the year after the official publication of the original WHO classification, and in 2006, 5 years later, were reviewed to address the hypothesis that increased familiarity with the new classification system would impact rates of diagnostic revision at expert pathology review. The WHO system, updating the REAL classification and reinforcing the central importance of morphology and immunophenotype in defining distinct clinicopathologic entities, offered the promise of a unified lexicon and pathologic approach to the rendering of an accurate and precise diagnosis of lymphoma.
Nonetheless, rates of major diagnostic revision at review by hematopathology at our center, or by another NCI-CCC before consultation at our center, were not significantly different in 2001 or in 2006 (21.3% and 18.6%, respectively, P = 0.35). In both periods, individuals referred with diagnosed lymphoma were reclassified as having benign conditions: 0.3% in 2001 and original articles Annals of Oncology this additional testing was intended to confirm a suspected change in diagnosis, rather than itself single-handedly lead to a new diagnosis. Notably, a consortium of five NCCN centers reported a pathology discordance rate of 6% (43 cases total) with diagnosis at referral [15] . Of these 43 cases, 44% were rendered without additional studies, 21% with additional biopsies and 26% with additional studies, usually IHC. It is unclear why our discrepancy rate is higher than this NCCN consortium, although referral bias, geographic regional variability, and differences in pathology review practices are possibilities. Our data do not support the a priori hypothesis that rates of diagnostic discrepancy would be lower for cases originally diagnosed at another NCI-CCC before consultation at our center. There may be several factors that bias our findings toward the null: referral patterns at our center are such that few patients are seen having been originally seen at a public hospital or having had specimens reviewed only by commercial laboratories. Further, it is likely that patients who were seen previously at another NCI-CCC and sought an additional opinion at our center represent a highly selected group of patients. It is possible that such patients may in part self-select due to perceived diagnostic challenges, which would inflate the odds of diagnostic discrepancy for this group. This is further supported by the nature of the discrepant cases, as many of these occurred in diagnoses with recognized diagnostic imprecision, such as discriminating CD20+ classical HL from primary mediastinal DLBCL. Similarly, caution must be exercised in extrapolating these findings to the general population of patients with lymphoma, as the entire cohort of patients seeking a second opinion at an NCI-CCC is a selected population, biasing the overall results in a similar fashion.
As lymphoma pathologists and clinicians now begin to assimilate the newest WHO classification into practice, it is time to ask what impact the previous revisions had on the ability to render accurate and reproducible diagnosis. Unfortunately, the persistence of high rates of major revision after 5 years of experience with the original WHO schema argues that the risk of misdiagnosis remains a clinical challenge, undermining the ability to capitalize on improvements in management for specific lymphoma subtypes. While a gold standard is difficult to define in cases of major diagnostic discrepancies, expert hematopathology review is a common practice among centers of excellence. Given both the high rates of major diagnostic revision and the potential for harm when management decisions are based upon erroneous diagnoses, a clear rationale exists for routine expert second-opinion review of diagnoses of lymphoma. 
